Treatment of Multiple Sclerosis With Copaxone and Albuterol
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone
compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS).
MS is thought to be an autoimmune disease of the central nervous system. Certain white blood
cells of the immune system become abnormally active and mistakenly attack the myelin of nerve
fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like
insulation around an electrical wire. Without proper myelin insulation, messages sent between
the brain and other parts of the body may be confused or fail completely. Damage to myelin
causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR),
where partial or total recovery occurs after attacks. Four therapies are currently approved
for the treatment of MS. These therapies, however, are only moderately effective and can
cause undesirable side effects. For this reason, there is a need to find new therapies that
have minimal side effects and may stop the disease from getting worse.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)